Snipr Biome CEO delighted over FDA fast-track status

CEO Christian Grøndahl now looks forward to more communication with the FDA, which could allow for Snipr Biome’s drug candidate to reach the market faster than before.

Christian Grøndahl, co-founder and CEO of Snipr Biome | Photo: EY / PR

Co-Founder and CEO at Snipr Biome Christian Grøndahl is very excited about the fact that the US Food and Drug Administration (FDA) recently awarded its special fast-track designation to the biotech company’s candidate, SNIPR001.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs